title: Embryonic dopamine cell implants as a treatment for the second phase of Parkinson's disease. Replacing failed nerve terminals.
authors.affiliation: Department of Medicine, University of Colorado School of Medicine, Denver 80262.
authors.forename: C R
authors.initials: CR
authors.lastname: Freed
authors.forename: R E
authors.initials: RE
authors.lastname: Breeze
authors.forename: N L
authors.initials: NL
authors.lastname: Rosenberg
authors.forename: S A
authors.initials: SA
authors.lastname: Schneck
mesh_terms: D000978:Antiparkinson Agents / Q000008:administration & dosage; D016380:Brain Tissue Transplantation / Q000502:physiology*; D002421:Caudate Nucleus / Q000503:physiopathology / Q000601:surgery; D003131:Combined Modality Therapy; D004292:Dominance, Cerebral / Q000502:physiology; D004298:Dopamine / Q000502:physiology*; D005260:Female; D016332:Fetal Tissue Transplantation / Q000502:physiology*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009416:Nerve Regeneration / Q000502:physiology*; D009460:Neurologic Examination; D010300:Parkinson Disease / Q000503:physiopathology / Q000601:surgery*; D011699:Putamen / Q000503:physiopathology / Q000601:surgery; D011954:Receptors, Dopamine / Q000502:physiology*
chemical_list: D000978:Antiparkinson Agents; D011954:Receptors, Dopamine; D004298:Dopamine